目的 探讨TMPRSS2-ERG融合基因在中国人群前列腺癌中的发生率以及其临床病理特征和对内分泌治疗的预后价值.方法 收集2010年10月到2014年12月前列腺癌穿刺活检标本96例及病例临床病理资料.所有患者均接受内分泌治疗.利用荧光原位杂交技术检测标本中TMPRRS2-ERG融合基因.比较融合基因阳性和阴性患者的临床病理资料分布及预后差异.结果 患者年龄范围为51~93岁,中位年龄为77岁;PSA范围为5.0-5000.0ng/mL.Gleason评分<7分的有6例(6.3%),Gleason评分=7分的有38例(39.6%),Gleason评分>7分的有52例(54.2%).临床分期T1-T2有32例,T3-T4有64例;M0为35例,M1为61例.穿刺标本TMPRSS2-ERG阳性有19例(19.8%).缺失型重排有11例,易位型重排亦有11例,同时含有缺失型和易位型重排患者共3例.融合基因阳性和阴性患者在年龄、PSA、Gleason评分、主要Gleason分级、T分期及M分期的临床分布及内分泌治疗预后方面差异均不具有统计学意义(P>0.05).结论 中国人群的前列腺癌TMPRSS2-ERG融合基因的发生率与日韩等亚洲国家人群基本一致,约为20%,远低于欧美人群.TMPRSS2-ERG融合基因阳性和阴性患者的年龄、治疗前PSA水平、Gleason评分、主要Gleason分级以及临床分期的分布不存在差异,同时其对内分泌治疗患者的预后不具备预测价值.%Objective To investigate the prevalence of TMPRSS2-ERG gene fusion in Chinese prostate cancer and its correlation with clinicopathologic parameters, as well as its prognostic significance for patients with endocrine therapy.Methods Total of 96 needle biopsy samples of patients with prostate cancers were collected from October, 2010 to December, 2014, and their clinical data was collected. All patients received endocrine therapy and were followed up. Fluorescence in situ hybridization (FISH) was used to detect TMPRSS2-ERG gene fusion in these specimens.Results TMPRSS2-ERG gene fusion accounted for 19.8% (19 cases), deletion pattern 57.9% (11cases) and translocation pattern 57.9% (11). 3(15.8%) had both deletion and insertion pattern. There were no significant differences between fusion positive and negative cases in the distribution of age (0.348), PSA(0.525), Gleason score(0.348), primary Gleason pattern (0.52), T stage (0.856) and metastasis (0.622). Similarly, no difference was observed between fusion positive and negative cases in progression free time (PFS) of these patients.Conclusion The prevalence of TMPRRSS2-ERG gene fusion is significantly lower in Chinese population than the western countries. TMRPSS2-ERG gene fusion is not correlated with age, PSA, Gleason score, primary Gleason pattern and TNM stage. It has no prognostic value for patients who received endocrine therapy.
展开▼
